These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10622226)

  • 1. The evolving role of oral topotecan.
    Burris HA
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):26-32. PubMed ID: 10622226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of phase I clinical studies with topotecan.
    Rowinsky EK; Verweij J
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-3-S20-10. PubMed ID: 9425956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan in the treatment of gynecologic cancer.
    Coleman RL; Miller DS
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
    Traina TA; Sabbatini P; Aghajanian C; Dupont J
    Gynecol Oncol; 2004 Oct; 95(1):235-41. PubMed ID: 15385138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
    Guichard S; Montazeri A; Chatelut E; Hennebelle I; Bugat R; Canal P
    Clin Cancer Res; 2001 Oct; 7(10):3222-8. PubMed ID: 11595718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
    Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
    J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
    Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
    Sood AK; Lush R; Geisler JP; Shahin MS; Sanders L; Sullivan D; Buller RE; Sorosky JI
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6080-5. PubMed ID: 15447993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based models for topotecan-induced neutropenia.
    Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
    Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
    J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of oral topotecan in hematological malignancies.
    Beran M; O'Brien S; Thomas DA; Tran HT; Cortes-Franco JE; Giles F; Estey E; Kantarjian HM
    Clin Cancer Res; 2003 Sep; 9(11):4084-91. PubMed ID: 14519630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
    Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
    Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of topotecan in the treatment of advanced breast cancer.
    Chang AY
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-49-S20-54. PubMed ID: 9425961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.